A new study from researchers at Moffitt Cancer Center shows that blocking a chemical process called nitrosylation could make one of the most aggressive forms of melanoma more treatable.
Michael J. Schell, Ph.D., interim chief in the Quantitative Science Division at Moffitt Cancer Center, has been elected a Fellow of the American Statistical Association (ASA), the world鈥檚 largest community of statisticians and data scientists. This prestigious honor recognizes his exceptional contributions to statistical sciences and his commitment to advancing the field.
Researchers from Moffitt Cancer Center will present data on the latest advances in cancer science and medicine at the American Association for Cancer Research (AACR) Annual Meeting 2025, which will take place April 25-30 in Chicago. Follow us @Moffitt麻豆传媒 for updates.
Researchers at Moffitt Cancer Center have found that tapping into the body鈥檚 own immune system and activating a type of immune cell known as B cells, could be the key to boosting the effectiveness of tumor-infiltrating lymphocyte, or TIL therapy. Results of their study were published in the Journal for Immunotherapy of Cancer.
A multi-institutional study led by Moffitt Cancer Center found that percutaneous hepatic perfusion using a melphalan hepatic delivery system may help patients with a rare eye cancer that has spread to their liver. This disease, known as metastatic uveal melanoma, is traditionally very hard to treat and usually has poor outcomes.
Moffitt Cancer Center researchers have discovered a promising new vaccine strategy for treating a specific type of breast cancer. The innovative approach targets human epidermal growth factor receptor 2-positive, estrogen receptor-negative (HER2-positive, ER-negative) breast cancer and has shown encouraging results in a recent pilot study. Published in npj Breast Cancer, the study combined the HER2-targeting dendritic cell vaccines with standard chemotherapy, demonstrating both safety and positive response rates.
Researchers from Moffitt Cancer Center have found a new way to boost cancer immunotherapy by targeting a protein called macrophage receptor with collagenous structure, or MARCO.
Moffitt Cancer Center has become the first standalone cancer center in the world to open a Nikon Center of Excellence. This prestigious achievement highlights Moffitt鈥檚 commitment to cutting-edge imaging technology and groundbreaking cancer research.
A new Moffitt Cancer Center study has identified a specific immune response that may prevent the spread of breast cancer cells within the body. Published in Cancer Immunology Research, the study shows that activating certain immune cells can stop dormant cancer cells from growing into new tumors.
A new community-based pickleball program called Project Rally is helping cancer survivors improve their physical and social well-being, according to a recent pilot study led by researchers at Moffitt Cancer Center. The program, which is offered in partnership with the YMCA of the Suncoast, has shown strong results in terms of participation, enjoyment, and physical improvements.
A new study from Moffitt Cancer Center could help doctors predict how well patients with a specific type of lung cancer will respond to new therapies. The research, published in Clinical Cancer Research, found that measuring the interaction between two proteins, RAS and RAF, could provide valuable insights into the effectiveness of treatments for patients with KRASG12C-mutant non-small cell lung cancer, a type of lung cancer known for being particularly difficult to treat.
A new study led by researchers from Moffitt Cancer Center, in collaboration with investigators from the University of Michigan, shows that artificial intelligence (AI) can help doctors make better decisions when treating cancer. However, it also highlights challenges in how doctors and AI work together. The study, published in Nature Communications, focused on AI-assisted radiotherapy for non-small cell lung cancer and hepatocellular carcinoma (liver cancer).
A new study led by researchers at Moffitt Cancer Center shows that asymptomatic brain metastasis is more common in stage 4 breast cancer patients than previously believed. The study, published in Neuro-Oncology, suggests that doctors may need to rethink current screening guidelines for detecting brain metastasis in patients without symptoms.
A new review led by researchers at Moffitt Cancer Center assessed how three genomic tests 鈥� Decipher, Oncotype DX Genomic Prostate Score (GPS) and Prolaris 鈥� can help doctors make better decisions about how to treat patients with early stage prostate cancer. The review, published in the Annals of Internal Medicine, shows that these tests can provide more detailed information about the cancer, but experts say more data is needed on the cost-effectiveness and clinical utility of these tests, as well as their impact on racial and ethnic groups, especially Black men.
Tiffany Carson, Ph.D., co-leader of Health Outcomes and Behavior Program at Moffitt Cancer Center, has been elected as a Fellow in the Academy of Behavioral Medicine Research (ABMR), recognizing her outstanding contributions to the field of behavioral medicine.
A new study has uncovered an unexpected way cancer cells can escape the immune system, making it harder for treatments to work. The study, published in Cancer Cell, explains how a type of cancer cell death can actually make tumors grow faster by turning off the immune system鈥檚 ability to fight the cancer.
A new study has found a surprising link between high levels of methylmalonic acid and the weakening of CD8+ T cells, shedding light on potential pathways through which aging may promote lung cancer progression. Moffitt Cancer Center researchers have found new insights into how metabolic changes associated with aging can impact immune responses against tumors.
A new study has unveiled crucial information about the incidence and risk factors of oral human papillomavirus (HPV) infections among men in the United States, Mexico and Brazil. Moffitt Cancer Center researchers have discovered how often new oral HPV infections occur, the factors influencing their acquisition and the regional variations in infection rates.
TAMPA, Fla. - A new study published in Cell Press reveals critical insights into the role of gamma-delta T cells across 33 cancer types, shedding light on their potential as clinical biomarkers and therapeutic targets in cancer treatment. Led by a team of researchers at Moffitt Cancer Center, this comprehensive analysis represents a significant advancement in the understanding of these unique immune cells and their implications for patient outcomes in cancer therapy.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal 麻豆传媒 keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right